Treace(US:TMCI) Prnewswireยท2025-05-22 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit alleging misleading statements and failure to disclose critical information that affected the company's stock value during the specified class period [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants' positive statements regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of the company's stock [3].